Search results
Apr 18, 2024 · Topline data from two late-stage monotherapy trials for the candidate in PD are expected in H2 2024. In December, AbbVie ( ABBV) agreed to acquire Cerevel ( CERE) for $8.7B. With CERE being a ...
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline. Find the latest Cerevel Therapeutics Holdings, Inc. (CERE) stock quote, history, news and other vital information to help you with your stock trading and investing.
Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
May 21, 2024 · Billion Dollar Secret. View Cerevel Therapeutics Holdings, Inc CERE investment & stock information. Get the latest Cerevel Therapeutics Holdings, Inc CERE detailed stock quotes, stock data, Real ...
May 22, 2024 · A high-level overview of Cerevel Therapeutics Holdings, Inc. (CERE) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
May 23, 2024 · See the latest Cerevel Therapeutics Holdings Inc Ordinary Shares stock price (CERE:XNAS), related news, valuation, dividends and more to help you make your investing decisions.
Cerevel Therapeutics Hldg Inc (CERE) Company Description. Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity.
